EVAX Q2 2024 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena

EVAXEvaxion Biotech A/S

$20M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$154,000

Gross Profit

$154,000100.0% margin

Operating Income

-$5M-2974.7% margin

Net Income

-$6M-4024.7% margin

EPS (Diluted)

$-4.60

QoQ Revenue Growth

+202.0%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$15M

Total Liabilities

$14M

Stockholders' Equity

$1M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$154,000	$0	—
Gross Profit	$154,000	$0	—
Operating Income	-$5M	-$6M	+19.3%
Net Income	-$6M	-$6M	-9.1%